— Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net loss of $1.49 per share, vs. $4.99 per share last year.
— Net loss was $21.5 million compared to $20.4 million last year.
— Research and development expenses were $15.5 million versus $16.9 million for 2018.
— Cash and cash equivalents as of December 31, 2019, totaled $22.7 million, compared to $17 million as of December 31, 2018.
Most Popular
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q2 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported its second quarter 2024 earnings results today. Net sales increased 4.9% year-over-year to $5 billion. Organic sales increased 9%. Net income attributable to Colgate-Palmolive Company was $731
Key takeaways from Visa’s Q3 2024 earnings report
Credit card behemoth Visa, Inc. (NYSE: V) this week reported mixed results for the June quarter, with earnings matching expectations and sales slightly missing the view. Both numbers grew in
Southwest Airlines (LUV): A look at the airline’s performance in Q2 2024
Shares of Southwest Airlines Co. (NYSE: LUV) were up over 6% on Thursday after the company beat earnings estimates for the second quarter of 2024. The stock has gained 4%
